Brain cancer is one of the most varied cancer types from a life insurance underwriting perspective. A meningioma survivor and a glioblastoma survivor face completely different situations when applying for life insurance — even though both are technically "brain cancer." Understanding which tumor type and grade you had, what treatment you received, and how long you've been in remission is essential before approaching any insurer. This guide walks through the full picture, tumor type by tumor type.

Why Brain Tumor Underwriting Requires Tumor-Specific Evaluation

The term "brain cancer" covers an extraordinarily diverse range of tumors with very different biology, treatment approaches, and prognoses. Insurers who specialize in impaired-risk underwriting know this distinction well. A general broker who submits a "brain cancer" application without specifying the tumor type, WHO grade, IDH mutation status, and surgical outcome is likely to receive a decline or an unnecessarily unfavorable offer. The most important piece of information you can bring to a life insurance application after a brain tumor diagnosis is your pathology report — specifically the tumor type, WHO grade, and any molecular markers that were tested.

WHO Grading System: The Foundation of Brain Tumor Underwriting

The World Health Organization (WHO) grading system classifies brain tumors from Grade 1 (slowest growing, most benign behavior) to Grade 4 (fastest growing, most aggressive). This grading is central to underwriting decisions:

  • WHO Grade 1: Slow-growing, often curable with surgery alone. Examples include pilocytic astrocytoma and many meningiomas. Most favorable underwriting outcome for brain tumors — some carriers will consider standard or near-standard rates after sufficient remission.
  • WHO Grade 2: Slower-growing but with greater tendency toward recurrence and potential progression to higher grades over time. Examples include low-grade diffuse gliomas with IDH mutations. Traditional coverage is possible after 5+ years of documented clean follow-up at certain specialty carriers, often with table ratings.
  • WHO Grade 3: Malignant, faster-growing tumors. Examples include anaplastic astrocytoma and anaplastic oligodendroglioma. Traditional coverage after Grade 3 tumors is significantly more limited. Long remission periods (7–10+ years) may open limited options at specialty carriers.
  • WHO Grade 4: The most aggressive grade. Glioblastoma multiforme (GBM) is the most common Grade 4 brain tumor. Standard and simplified issue life insurance is generally not available. Guaranteed issue is the primary accessible option for most GBM patients and survivors.

Tumor Types: What Insurers Need to Know

Meningioma

Meningiomas arise from the meninges (the membranes surrounding the brain and spinal cord) and are the most common primary brain tumor in adults. The majority of meningiomas are WHO Grade 1 — benign and slow-growing. They are often found incidentally on imaging done for other reasons and may be managed with observation (watchful waiting) rather than immediate treatment.

For life insurance purposes, meningioma underwriting is generally more favorable than most other brain tumors. Key factors include:

  • Grade: WHO Grade 1 meningiomas after complete surgical resection with clean follow-up are insurable at many carriers, often at standard or near-standard rates after 2–5 years.
  • Resection status: Simpson Grade I or II surgical resection (complete removal) is the most favorable outcome. Higher Simpson grades (incomplete removal) increase recurrence risk and affect underwriting.
  • Grade 2 (atypical) meningioma: Associated with higher recurrence risk. Table ratings and longer waiting periods apply. Some carriers will consider applications after 5+ years of clean follow-up.
  • Grade 3 (anaplastic) meningioma: Rare and more aggressive. Underwriting is limited. Guaranteed issue is often the realistic near-term option.
  • Observation only: If your meningioma is being monitored without treatment, disclosure is still required and underwriting depends on tumor size, location, and rate of growth on serial imaging.

Glioblastoma (GBM) — WHO Grade 4

Glioblastoma multiforme is the most common malignant primary brain tumor in adults and carries one of the most challenging prognoses of any cancer type. Median survival after diagnosis with standard treatment (surgery, radiation, and temozolomide chemotherapy) is approximately 15–18 months, though a meaningful subset of patients survive well beyond this median.

For life insurance purposes, glioblastoma presents the most constrained underwriting environment:

  • Traditional term and permanent life insurance are generally not available during active treatment or in the early post-treatment period.
  • Guaranteed issue life insurance ($5,000–$25,000, 2-year graded benefit) is the most accessible option for most GBM patients.
  • Long-term GBM survivors — defined as 5+ years after diagnosis — represent a distinct biological group where some specialty carriers may consider simplified issue applications on a case-by-case basis. This is a small population, and coverage amounts would be limited even if approved.
  • Group life insurance through an employer remains accessible during open enrollment regardless of health status and should be maximized.
  • Existing policy accelerated death benefit riders (terminal illness riders) may be activatable depending on physician prognosis certification and policy terms.

Low-Grade Gliomas (WHO Grade 2) — Diffuse Astrocytoma and Oligodendroglioma

Low-grade gliomas have significantly better outcomes than glioblastoma, though they carry meaningful long-term recurrence and progression risk. The 2016 WHO classification introduced molecular markers — particularly IDH mutation status and 1p/19q codeletion — that have significantly changed how these tumors are categorized and treated.

  • IDH-mutant oligodendroglioma (IDH mutant, 1p/19q codeleted): Among the most favorable low-grade glioma subtypes. Median survival is measured in decades for some patients. Some specialty carriers will consider traditional coverage after 5–7 years of clean imaging and documented stable remission.
  • IDH-mutant astrocytoma (Grade 2): Better prognosis than IDH-wildtype tumors but with meaningful progression risk. Traditional coverage may be possible at specialty carriers after 7–10 years of clean follow-up.
  • IDH-wildtype diffuse glioma (Grade 2): Often behaves more aggressively than IDH-mutant tumors and is now understood to be biologically closer to glioblastoma in many cases. Underwriting is significantly more restrictive.

Having your molecular marker results (IDH mutation status, MGMT methylation, 1p/19q codeletion) documented and available when applying is important — these details meaningfully affect underwriting outcomes at specialty carriers.

Anaplastic Gliomas (WHO Grade 3)

Anaplastic astrocytoma, anaplastic oligodendroglioma, and other Grade 3 gliomas occupy a middle ground between low-grade gliomas and glioblastoma in terms of both prognosis and underwriting. Traditional life insurance is rarely available in the first 5–7 years after diagnosis. After 7–10 years of documented remission, some specialty carriers may consider applications for IDH-mutant Grade 3 tumors with favorable molecular profiles, typically with significant table ratings.

Primary Central Nervous System Lymphoma (PCNSL)

PCNSL is a rare form of non-Hodgkin lymphoma confined to the brain and spinal cord. It is treated with high-dose methotrexate-based chemotherapy rather than the surgical approaches used for gliomas. From an underwriting perspective, PCNSL is evaluated similarly to systemic lymphoma with CNS involvement — prognosis, treatment response, and remission duration are the primary factors. Long-term remission (5+ years) in the absence of systemic involvement may allow traditional coverage consideration at specialty carriers familiar with lymphoma underwriting.

Brain Metastases (Secondary Brain Cancer)

Brain metastases — cancer that has spread to the brain from a primary tumor elsewhere in the body — are different from primary brain tumors and are underwritten according to the primary cancer type and overall disease status. If you have brain metastases, your underwriting is driven by your primary cancer (breast, lung, melanoma, kidney, etc.), the extent of systemic disease, and treatment response. Brain involvement typically indicates Stage IV disease for solid tumors, which significantly constrains traditional coverage options. Guaranteed issue remains available.

Key Documentation to Gather Before Applying

Regardless of which brain tumor type you had, gathering complete documentation before working with a specialty broker significantly improves the process:

  • Pathology report with tumor type, WHO grade, and all molecular markers tested (IDH mutation, MGMT methylation, 1p/19q codeletion, TERT promoter mutation)
  • Operative report and neurosurgeon's note regarding extent of resection
  • Radiation oncology records if radiation was given (type, dose, field)
  • Oncology or neuro-oncology follow-up notes showing current status
  • Most recent MRI report with radiologist's interpretation (ideally stating "no evidence of disease" or "stable post-treatment changes")
  • Complete treatment summary

Realistic Coverage Options After Brain Cancer

WHO Grade 1 Tumors (Meningioma, Pilocytic Astrocytoma) — Post-Resection

These represent the most favorable brain tumor underwriting scenario. After 2–5 years of clean imaging follow-up and complete or near-complete surgical resection, traditional fully underwritten life insurance is accessible at multiple carriers, often at standard or near-standard rates. Work with a general or specialty broker who is comfortable presenting a Grade 1 meningioma history — this is not a case that requires the most specialized impaired-risk broker.

WHO Grade 2 IDH-Mutant Tumors — Long-Term Remission

After 5–10 years of documented clean remission with favorable molecular markers, traditional coverage is possible at specialty carriers at above-standard rates. Working with a broker experienced in neuro-oncology cases is valuable. Coverage amounts of $500,000 and above are achievable for the best-profile applicants in this group.

WHO Grade 3–4 Tumors — Current or Recent

Guaranteed issue life insurance is the primary accessible option. Employer group coverage during open enrollment should be maximized. Existing policy accelerated benefits should be reviewed. Viatical settlements may be applicable for existing policies if prognosis is significantly limited.

Long-Term GBM Survivors (5+ Years)

This is a biologically distinct group that represents a small minority of GBM diagnoses. Simplified issue coverage may be available through some specialty carriers willing to evaluate long-term GBM survivors individually. Coverage amounts are limited. This requires a highly specialized broker with experience in this specific underwriting niche.

Working with a Specialty Broker

Brain tumor underwriting requires a broker with genuine impaired-risk expertise. The specific tumor type, WHO grade, and molecular markers are not details a general broker will know how to present effectively. A specialty broker who regularly works with brain tumor cases knows which carriers distinguish between meningioma and glioblastoma, which carriers have the most favorable guidelines for IDH-mutant low-grade gliomas with long remission, and which carriers are most likely to decline regardless of history. The informal shopping process — presenting your profile to multiple carriers without formal application — is essential to avoid unnecessary MIB record entries from formal declines.

Cancer Series: Related Guides

This guide is part of our life insurance after cancer series. See the complete list at our Life Insurance After Cancer hub page.

This content is for informational purposes only and does not constitute insurance, financial, or legal advice. Life insurance availability and rates after a brain tumor diagnosis depend on individual tumor type, grade, molecular markers, treatment history, and remission duration, and vary significantly by carrier. Always consult a licensed life insurance professional with impaired-risk experience before making coverage decisions.